OCTOBER 26, 2020

The Role of Biomarkers In the Management Of Barrett’s Esophagus

Potential to optimize therapy, surveillance, and screening

Ashton Ellison, MB ChB

Department of Medicine
Baylor University Medical Center
Dallas, Texas

Vani Konda, MD

Department of Medicine
Baylor University Medical Center
Baylor Scott and White Center of Esophageal Diseases
Dallas, Texas

It is well established that selected patients with high-grade dysplasia (HGD)/esophageal adenocarcinoma (EAC) benefit from endoscopic therapy with an acceptable risk profile, but we have yet to develop selection criteria to determine which patients with Barrett’s

To read the full story, Log in or Sign up for a Free Account

Esophageal Disorders

Potential to optimize therapy, surveillance, and screening